RecruitingPHASE1, PHASE2NCT06662188
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
Studying Phelan-McDermid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jaguar Gene Therapy, LLC
- Principal Investigator
- Dan Gallo, PhDJaguar Gene Therapy
- Intervention
- JAG201(genetic)
- Enrollment
- 6 enrolled
- Eligibility
- 2-9 years · All sexes
- Timeline
- 2024 – 2031
Study locations (3)
- Rush University, Chicago, Illinois, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Seaver Autism Center at Mount Sinai, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06662188 on ClinicalTrials.govOther trials for Phelan-McDermid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07281079A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid SyndromeNeuren Pharmaceuticals Limited
- RECRUITINGNANCT07014020RB001 Gene Therapy Study in Children With SHANK3-related Phelan McDermid Syndrome (PMS)Peking University First Hospital
- ACTIVE NOT RECRUITINGNCT02461420Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid SyndromeBoston Children's Hospital